Kairos Pharma Ltd. (KAPA)
Kairos Pharma Ltd. (KAPA) Stock Price, Analysis & Data
Keine Daten verfügbar
| Geld | n/a |
| Marktkapitalisierung | 6.64 Mio |
| Umsatz (TTM) | n/a |
| Nettogewinn (TTM) | -5.8 Mio |
| Beta | n/a |
| EPS (ttm) | -0.28 |
| KGV (TTM) | n/a |
| Forward-KGV | -0.46 |
| KBV (TTM) | 1.02 |
| KUV (TTM) | n/a |
| Earnings Date | n/a |
| Brief | n/a |
| Volumen | 207,272 |
| Ø Vol. (20D) | 2,194,508 |
| Eröffnung | 0.32 |
| Vortagesschluss | 0.32 |
| Tagesspanne | 0.31 - 0.32 |
| 52-Wk Range | 0.27 - 2.11 |
| Analyst | n/a |
| Kursziel | n/a |
| Dividenden | n/a |
| Ex-Dividenden-Datum | n/a |
Über KAPA
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer. The company offers therapeutics, including antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. It also develops ENV 105, an antibody therapeutic that is in a Phase 2 clinical trial for prostate cancer patients resistant to androgen-targeted therapy, a...
Finanzielle Entwicklung
Im Jahr 2025 betrug der Umsatz von Kairos Pharma 0, ein Anstieg von undefined% im Vergleich zum Vorjahr (0). Der Gewinn lag bei -5.45 Mio, ein Anstieg von 109.26 %.
FinanzberichteGewinnüberraschung
vor 2 Wochen · Simply Wall St.
Bayer (XTRA:BAYN) Stock Still Looks Reasonable On New Prostate Cancer NewsBayer’s share price has climbed sharply over the past year, yet the valuation checks still suggest the stock screens as cheap on several measures. This raises the question of how much of the recent op...
